Literature DB >> 7130244

"Activated" monocytes in gastric cancer patients. I. Increased Fc receptor expression, antibody-dependent cellular cytotoxicity and NBT reduction.

W Uracz, A Pituch-Noworolska, M Zembala, T Popiela, A Czupryna.   

Abstract

The Fc receptor expression, antibody-dependent cellular cytotoxicity (ADCC), and nitro-blue tetrazolium (NBT) reduction of peripheral blood monocytes from 150 patients with different stages of gastric cancer was assessed and compared with results obtained in 77 normal persons and 104 patients with non-malignant diseases of the gut. Monocytes of cancer patients showed an increased ability to form rosettes with human 0, Rh + erythrocytes coated with D-specific antibody. ADCC and NBT reduction were also elevated but no correlation was found with the stage of disease. However, all these phenomena were related to the tumor load as elevated values were the same 4-6 months after surgery in the unresectable-tumor group, while they decreased in patients with resectable tumors. These observations suggest that monocytes of some cancer patients are functionally altered ("activated") in the course of disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7130244     DOI: 10.1007/bf00402066

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Altered expression of human monocyte Fc receptors in malignant disease.

Authors:  J Rhodes
Journal:  Nature       Date:  1977-01-20       Impact factor: 49.962

2.  Recognition and destruction of target cells by tumoricidal macrophages.

Authors:  I J Fidler
Journal:  Isr J Med Sci       Date:  1978-01

3.  Monocyte function in cancer patients.

Authors:  J G McVie; E C Logan; A B Kay
Journal:  Eur J Cancer       Date:  1977 Apr-May       Impact factor: 9.162

Review 4.  Activation of mononuclear phagocytes: fact, fancy, and future.

Authors:  Z A Cohn
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

5.  Isolation of functional subsets of human peripheral blood monocytes.

Authors:  D A Norris; R M Morris; R J Sanderson; P F Kohler
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

6.  Tumor surveillance: how tumors may resist macrophage-mediated host defense.

Authors:  J Rhodes; M Bishop; J Benfield
Journal:  Science       Date:  1979-01-12       Impact factor: 47.728

7.  Activation of human monocytes for nitroblue tetrazolium reduction and the suppression of lymphocyte response to mitogens.

Authors:  M Zembala; E M Lemmel; W Uracz
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

8.  Monocytes and macrophages in malignant melanoma. III. Reduction of nitroblue tetrazolium by peripheral blood monocytes.

Authors:  D W Hedley; G A Currie
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640

9.  Monocytes and macrophages in malignant melanoma. II. Lysis of antibody-coated human erythrocytes as an assay of monocyte function.

Authors:  R E Nyholm; G A Currie
Journal:  Br J Cancer       Date:  1978-03       Impact factor: 7.640

10.  Monocyte chemotaxis in bronchial carcinoma and cigarette smokers.

Authors:  A B Kay; J G McVie
Journal:  Br J Cancer       Date:  1977-10       Impact factor: 7.640

View more
  7 in total

1.  The role of shed Fc receptor in the regulation of lymphocyte response to phytohaemagglutinin (PHA).

Authors:  A Pituch-Noworolska; J Noworolski; J Pryjma; M Zembala
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

2.  Monocyte antibody-dependent cellular cytotoxicity in cancer patients.

Authors:  N J De Young; P G Gill
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Recombinant interferon gamma up-regulates in vivo and down-regulates in vitro monocyte CD14 antigen expression in cancer patients.

Authors:  R Landmann; M Wesp; C Ludwig; R Obrist; C Knüsli; J P Obrecht
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Antibody-dependent cell-mediated cytotoxicity using a murine monoclonal antibody against human colorectal cancer in cancer patients.

Authors:  K Takamuku; T Akiyoshi; H Tsuji
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Serial immunological testing in patients with gastric cancer.

Authors:  M Zembala; T Popiela; D Kowalczyk; B Mytar; A Pituch-Noworolska; I Ruggiero; W Uracz; A Czupryna; H Labza
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

6.  The altered expression of MHC-class II determinants on monocytes of cancer patients.

Authors:  W Uracz; J Stachura; A Pituch-Noworolska; T Popiela; A Czupryna; M Zembala
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  "Activated" monocytes in gastric cancer patients. II. Suppressor and cytostatic activity in vitro.

Authors:  W Uracz; B Mytar; M Zembala; I Ruggiero; T Popiela; A Czupryna
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.